JP2007151932A - Iontophoretic apparatus - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an iontophoretic apparatus which permits the administration of dextran to the skin by iontophoresis. <P>SOLUTION: The iontophoretic apparatus 10 includes an action side electrode structure 20 and a nonaction side electrode structure 40. The action side electrode structure 20 includes an action side electrode 22 connected to a direct current power supply 12, an electrolyte holding portion 24, a second ion selective membrane 26, and a liquid medicine holding portion 28 in that order. The liquid medicine holding portion 28 has a hydrogel having adhesion to the skin, which is impregnated with a dextran sulfuric acid and/or a partially degraded dextran. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to an iontophoresis device for administering dextran to a living body.

  For example, as shown in Patent Document 1, skin and hair cosmetics mainly composed of dextran are known.

  In the said patent document 1, each component of sodium chloride, glucose, and dextran is related with the aqueous skin and hair cosmetics characterized by melt | dissolving in the water phase component at the temperature of 50-60 degreeC. In the invention described in Patent Document 1, an aqueous solution prepared by mixing sodium chloride, butter sugar, and dextran in water at a temperature of 50 to 60 ° C. and dissolving it on the skin is left to be applied to the skin. It is said that it is effective for pigmentation and gender alopecia, etc. by circulating tissue fluid and promoting active division of subcutaneous cells.

  In particular, by dissolving each of the above sodium chloride, buto sugar and dextran components in an aqueous phase component at a temperature of 50 to 60 ° C., it succeeded in creating an environment similar to the skin cell interstitial fluid on the skin surface. Has been.

  However, in practice, in order to make the cosmetics equivalent to the skin cell interstitial fluid, the above-mentioned effects are not obtained until the cosmetics are applied and remained on the epidermis and steamed for a relatively long time with, for example, a steam towel. It turns out that it is obtained.

  Moreover, it is well known that dextran not only has the effect of a moisturizing agent as a cosmetic additive, but is also used as a substitute plasma and blood flow improving agent.

  From the above facts, it can be expected that dextran acts like a cell interstitial fluid when it penetrates into the skin.

  On the other hand, in skin spots and alopecia, one of the causes is considered to be blockage of the flow of cell interstitial fluid from the dermis layer to the epidermis.

Japanese Examined Patent Publication No. 2-12443

  This invention can reliably administer dextran into the skin without dissolving dextran at a high temperature (50 to 60 ° C.) as in Patent Document 1 or applying it to the skin and using a steam towel for a long time. It is an object of the present invention to provide an apparatus as described above.

  As a result of intensive studies, the present inventors have found that dextran derivatives such as dextran sulfate and / or partially degraded dextran can be used and can be administered to the skin by iontophoresis.

  That is, the above-described problems can be solved by the following embodiments.

  (1) A working electrode structure and a non-working electrode structure used to administer drug ions by iontophoresis, and these working electrode structures and non-working electrode structures have different polarities. The working electrode structure is electrically connected to the working electrode connected to the same kind of polarity as the drug ions in the direct current power supply. A drug solution holding unit that holds the drug that becomes the drug ion, and the drug held in the drug solution holding unit is at least one of a dextran derivative and a partially decomposed dextran. Iontophoresis device.

  (2) The medicinal solution holding unit may impregnate the working side ion selective membrane that selectively allows the same kind of ions as the drug ions to pass through the drug, or the working side electrode of the working side ion selective membrane. The iontophoresis device according to (1), wherein the iontophoresis device is applied to the opposite side of the iontophoresis device.

  (3) The iontophoresis device according to (1), wherein the chemical solution holding unit is a mixture of the drug and a minute amount of gel.

  (4) An electrolytic solution holding unit, a second ion selective membrane, and a chemical solution replenishing unit are provided in this order from the working electrode side between the working electrode and the working ion selective membrane. The chemical solution replenishment part holds at least one of dextran sulfate and partially decomposed dextran, and the second ion selective membrane is configured to selectively pass ions opposite to the drug ions. The iontophoresis device according to (2), which is characterized.

  (5) A working electrode structure and a non-working electrode structure used to administer drug ions by iontophoresis, and the working electrode structure and the non-working electrode structure with different polarities. The working electrode structure is electrically connected to the working electrode connected to the same kind of polarity as the drug ions in the direct current power supply. A drug solution holding unit that holds the drug that becomes the drug ion, and a working ion selective membrane that is disposed in front of the drug solution holding unit and selectively allows the same kind of ions as the drug ion to pass therethrough. The non-working side electrode structure has a non-working side electrode connected to the polarity opposite to the drug ion in the DC power source, and is electrically connected to the non-working side electrode to hold the electrolyte solution. Electrolysis A holding part and a non-action-side ion selective membrane that is disposed in front of the electrolyte solution holding part and selectively allows ions opposite to the drug ions to pass therethrough, and is held in the chemical solution holding part An iontophoresis device, wherein the prepared drug is at least one of a dextran derivative and a partially degraded dextran.

  (6) The working electrode structure is disposed on the working electrode, on the front surface of the working electrode, on the front surface of the electrolytic solution holding section, and on the front surface of the electrolytic solution holding section. A second ion-selective membrane that selectively allows ions opposite to drug ions to pass through; the drug solution holding portion disposed on the front surface of the second ion selective membrane; An iontophoresis device according to (5), comprising a working side ion selective membrane.

  (7) The non-working side electrode structure includes the non-working side electrode, a second electrolytic solution holding unit that is disposed on the front surface of the non-working side electrode and holds the second electrolytic solution, and the second electrolytic solution. A third ion-selective membrane that is disposed in front of the holding unit and selectively allows the same kind of ions as the drug ions to pass through; a third electrolyte solution holding unit that is disposed in front of the third ion-selective membrane; The iontophoresis device according to (5) or (6), comprising the non-working side ion selective membrane disposed on the front surface of the third electrolyte solution holding unit.

  The ion selective membrane includes an ion exchange membrane and a porous membrane. The ion exchange membrane indicates a member having an ion exchange group, and the porous membrane has a large number of pores (continuous pores) in the membrane. The film | membrane which has is shown.

  In this invention, a dextran component and / or a partially decomposed dextran can be easily and reliably administered to a subcutaneous tissue by using a drug solution holding part in an iontophoresis device.

  An apparatus according to this best mode includes a working electrode structure and a non-working electrode structure used to administer drug ions by iontophoresis, and these working electrode structure and non-working electrode. A DC power source connected to the structure with a different polarity, and the working electrode structure includes a working electrode connected to the same kind of polarity as the drug ions in the DC power source, and the working electrode And a drug solution holding part that holds the drug that becomes the drug ion, and the drug held in the drug solution holding part is configured as a dextran derivative.

  Hereinafter, with reference to FIG. 1, the iontophoresis apparatus 10 which concerns on Example 1 of this invention is demonstrated in detail.

  The iontophoresis device 10 according to this embodiment includes a working electrode structure 20 and a non-working electrode structure 40 used for administering an ionic drug by iontophoresis, and these working electrodes. And a DC power source 12 connected to the structure 20 and the non-working side electrode structure 40 with different polarities.

  The working electrode structure 20 includes a working electrode 22 connected to the same kind of polarity (cathode) as a medicinal component (anion) in dextran sulfate serving as the drug ion in the DC power source 12, and the working electrode 22. And an electrolyte solution holding unit 24, a second ion-selective membrane 26, and a chemical solution holding unit 28 that holds dextran sulfate, which is one of the dextran derivatives.

  In the first embodiment, the chemical solution holding unit 28 is configured by impregnating hydrogel with dextran sulfate.

  This hydrogel is polyvinylpyrodopyrrolidone (PVP) that is electron beam cross-linked and has an average molecular weight of about 500,000 to 2 million, preferably about 900,000 to about 1.5 million. The hydrogel not only has sufficient adhesion to the human skin, but can be removed without damaging the skin.

  The non-working side electrode structure 40 is disposed in the DC power source 12 at a non-working side electrode 42 connected to a polarity (anode) opposite to the dextran sulfate ion (anion), and in front of the non-working side electrode 42. A second electrolyte solution holding unit 44 for holding the second electrolyte solution, and a second electrolyte solution holding unit 44 that is disposed in front of the second electrolyte solution holding unit 44 and selectively passes ions (anions) of the same kind as the dextran sulfate ions. 3 ion-selective membrane 46, a third electrolyte holding part 48 disposed on the front surface of the third ion selective film 46, and a non-working side ion selector arranged on the front surface of the third electrolyte solution holding part 48 And an ionic membrane (fourth ion selective membrane) 50.

  The working side electrode 22 in the working side electrode structure 20 and the non-working side electrode 42 in the non-working side electrode structure 40 are made of a conductive paint blended with a nonmetallic conductive filler such as carbon paste, for example. Although these electrodes can also be comprised with a copper plate or a metal thin film, since the metal eluted from this can transfer to a biological body at the time of chemical | medical agent administration, nonmetallic property is preferable.

  The electrolytic solution holding unit 24, the second and third electrolytic solution holding units 44 and 48 hold an electrolyte, and this electrolyte is an electrolytic reaction of water (oxidation at the positive electrode and reduction at the negative electrode). Electrolytes that are more easily oxidized or reduced, such as pharmaceutical agents such as ascorbic acid (vitamin C) and sodium ascorbate, organic acids such as lactic acid, oxalic acid, malic acid, succinic acid, fumaric acid and / or their salts It is particularly preferable that it is possible to suppress the generation of oxygen gas and hydrogen gas, and by blending a plurality of types of electrolytes that become a buffer electrolyte when dissolved in a solvent, It is also possible to suppress changes in pH during energization.

  The electrolyte solution holding parts 24, 44, and 48 may be any sheet having water retention, such as a fiber sheet such as gauze or filter paper, or a polymer gel sheet such as an acrylic resin hydrogel (acrylic hydrogel) or a segmented polyurethane gel. A carrier made of a material is impregnated or contained with an electrolyte solution. Moreover, what hold | maintains electrolyte solution in a liquid state may be used, and electrolyte paint may be used.

  The second ion selective membrane 26 contains an ion exchange resin into which an ion exchange group having a counter-conductivity ion opposite to dextran sulfate ion is introduced. Here, the medicinal component in the chemical solution holding unit 28 is an anion. Therefore, a cation exchange resin is blended.

  The non-working side electrode 42 in the non-working side electrode structure 40 is connected to the polarity opposite to the charged ion of the drug ion in the DC power supply 12.

  The second electrolyte solution holding unit 44 is configured to hold the second electrolyte solution. Further, the third ion selective membrane 46 is configured to selectively pass ions of the same kind as the charged ions of the drug ions. The third electrolyte solution holding unit 48 holds the third electrolyte solution, and the non-working side ion selective membrane 50 selectively passes ions opposite to the charged ions of the ionic drug. It is supposed to let you.

  Reference numeral 21 in FIG. 1 denotes a backing material constituting the outer shell of the working electrode structure 20, and 21 A denotes an inner periphery of the backing material 21, the working electrode 22, the electrolytic solution holding portion 24, and the second ion selective membrane 26. , And a molding material disposed between the outer periphery of the chemical solution holding portion 28, 21B is a flange portion on the lower surface of the backing material 21 in FIG. 2, 21C is an adhesive layer of the flange portion 21B, and 21D is a chemical solution holding portion. 28 shows a sealing film for sealing the outer surface in FIG.

  The non-working side electrode 42 has the same configuration as that of the working side electrode 22, and the configurations and components of the second electrolytic solution holding unit 44 and the third electrolytic solution holding unit 48 are the same as those of the electrolytic solution holding unit 24. It is the same.

  Further, the third ion selective membrane 46 functions as an ion selective membrane opposite to the second ion selective membrane 26.

  That is, the third ion selective membrane 46 is configured to select the same type of ion (anion) as the drug ion, and an ion having the same conductivity type as the drug ion in the drug solution holding unit 28 is used as a counter ion. An ion exchange resin into which an ion exchange group is introduced is included. That is, since dextran sulfate or the like in the chemical solution holding unit 28 dissociates into anions, it contains an anion exchange resin.

  Examples of the cation exchange resin include polymers having a three-dimensional network structure such as hydrocarbon resins such as polystyrene resins and acrylic resins, and fluorine resins having a perfluorocarbon skeleton, sulfonic acid groups, and carboxylic acids. An ion exchange resin into which a cation exchange group such as a group or a phosphonic acid group (an exchange group in which the counter ion is a cation) is introduced can be used without limitation.

  The anion exchange resin includes a polymer having the same three-dimensional network structure as the cation exchange resin, a primary to tertiary amino group, a quaternary ammonium group, a pyridyl group, an imidazole group, a quaternary group. An ion exchange resin into which an anion exchange group such as a pyridinium group or a quaternary imidazolium group (an exchange group in which the counter ion is an anion) is introduced can be used without limitation.

  The non-working side ion selective membrane 50 is formed including the ion exchange resin contained in the second ion selective membrane 26 similar to the above. The non-working side ion selective membrane 50 functions as an ion selective membrane equivalent to the second ion selective membrane 26.

  1 is a backing material constituting the outer shell of the non-working electrode structure 40, 41A is the inner periphery of the backing material 41, the non-working side electrode 42, the second electrolyte solution holding portion 44, the first The molding material 41B disposed between the outer periphery of the three ion selective membrane 46, the third electrolyte solution holding portion 48 and the non-working side ion selective membrane 50 is a flange portion on the lower surface of the backing material 41 in FIG. , 41C is a pressure-sensitive adhesive layer of the flange portion 41B, and 41D is a seal film for sealing the outer surface of the non-working side ion selective membrane 50 in FIG.

  As the DC power source 12, for example, a button battery or a thin battery disclosed in, for example, Japanese Patent Application Laid-Open No. 11-067236, US Patent Publication No. 2004 / 0185667A1, US Pat. No. 6,855,441, or the like can be used. The structure of the embodiment is not limited.

  The DC power source 12 is disposed integrally with the working side electrode structure 20 or the non-working side electrode structure 40, and the DC power source 12, the working side electrode structure 20, and the non-working side electrode structure 40 are connected to each other. They are connected by lead wires 14.

  In Example 1, after the seal films 21D and 41D are peeled off, the chemical solution holding portion 28 at the tip of the working electrode structure 20 is pressed against the portion of the skin where dextran is to be administered, and is adhered thereto. In addition, the non-working side ion selective membrane 50 at the tip of the non-working side electrode structure 40 is attached in close contact, so that the current from the DC power source 12 is applied to the working side electrode structure 20, the skin, and the non-working side electrode. A current is passed through the circuit of the structure 40.

  The dextran sulfate held in the chemical solution holding unit 28 becomes an anion when it is ionized. On the other hand, ions having the same polarity as the dextran sulfate flow in from the second ion selective membrane 26 side. 28 dextran sulfate ions penetrate into the skin.

  In order to penetrate into the skin, it is better that the molecular weight of the drug ion is small. However, since dextran sulfate has a minimum molecular weight of about 1600, it is optimal to use this. Usually, for such dextran sulfate, partially decomposed dextran having a molecular weight of 2000 to 4000 is used as a raw material. Therefore, only dextran sulfate and partially decomposed dextran or partially decomposed dextran may be held in the chemical solution holding unit 28.

  As described above, dextran sulfate and / or partially decomposed dextran can be held in the drug solution holding unit 28 and can be easily administered to the skin by iontophoresis.

  Furthermore, in this Example 1, since the chemical solution holding part 28 is composed of a hydrogel as described above and impregnated with dextran sulfate and / or partially decomposed dextran, it is surely adhered to the skin. When in contact, dextran sulfate and / or partially degraded dextran can be stably administered into the skin.

  As described above, other dextran derivatives may be used as the dextran sulfate used for the drug holding unit 28. Examples of other dextran derivatives include carboxymethyl dextran, cationized dextran, dextran methyl methacrylate copolymer, carboxymethyl dextran, felcarbotran (magnetic iron sulfide-dextran complex), dextran iron and the like.

  The iontophoresis device 60 according to the second embodiment is obtained by changing a part of the configuration of the iontophoresis device 10 according to the first embodiment, and the other configurations are the iontophoresis devices 10. Therefore, the same parts are denoted by the same reference numerals, and the description thereof is omitted. In FIG. 2, only the working electrode structure 62 is shown, and the non-working electrode structure is not shown.

  Whether the chemical solution holding unit 32 in the iontophoresis device 60 according to the second embodiment impregnates the first ion-selective membrane 33 with the drug that is the dextran sulfate and / or the partially decomposed dextran, or applies it to the skin side. (A coating mold is shown in FIG. 2).

  Here, the first ion-selective membrane (working side ion-selective membrane) 33 is similar to the third ion-selective membrane 46 so as to selectively pass the same kind of ions as the dextran ions, that is, anions. It is configured.

  In addition, a chemical solution replenishing unit 34 is disposed between the second ion selective membrane 26 and the chemical solution holding unit 32. The chemical solution replenishing unit 34 holds the same dextran sulfate and / or partially decomposed dextran as in the chemical solution holding unit 32.

  Further, a liner 36 is disposed between the chemical solution replenishment section 34 and the second ion selective membrane 26, and is configured to isolate the two when not in use (before use).

  The liner 36 can be removed from between the second ion-selective membrane 26 and the chemical solution replenishing portion 34 by pulling one end of the liner 36 from the outside.

  The pressure-sensitive adhesive layer 21C is attached in a state where the tip of the working electrode structure 21 is in close contact with the skin. Affixed to the skin near the body 21.

  Next, when the liner 36 is pulled out, the chemical solution replenishing section 34 and the second ion selective membrane 26 come into contact with each other, and a current from the DC power source 12 is supplied.

  In this Example 2, dextran sulfate ions are delivered from the drug solution holding part 32 into the skin, and from the first ion selective membrane 33 to the drug solution holding part 32. At this time, the dextran sulfate ion is an anion exchange membrane. In order to leave the anion from the ion exchange group of the first ion selective membrane 33, an anion that can be replaced by the front side thereof, that is, the chemical solution replenishment unit 34 is required. For this reason, dextran sulfate and / or partially decomposed dextran is also disposed in the chemical solution replenishment unit 34 to prevent the delivery of drug ions due to anion competition, and administration of dextran sulfate and / or partially decomposed dextran to the skin. Can be promoted.

  Furthermore, in the second embodiment, the liner 36 prevents the second ion selective membrane 26 and the drug in the drug solution replenishing portion 34 from coming into contact with each other, so that mixing due to diffusion of the electrode solution and the drug during the storage period is suppressed. be able to.

  Furthermore, in the second embodiment, since the first ion selective membrane 33 is impregnated or coated with dextran sulfate and / or partially decomposed dextran, there is an advantage that it can be adhered to the skin. . For example, the drug can be brought into close contact with the dents between the skin such as the sweat glands and pores of the skin, and the drug delivery efficiency can be improved.

  In Examples 1 and 2, the non-working side electrode structure 40 includes the non-working side electrode 42, the second electrolyte solution holding unit 44, the third ion selective membrane 46, the third electrolyte solution holding unit 48, and the non-working side electrode structure 40. The working ion selective membrane 50 is used, but the present invention is not limited to this, and the non-working electrode structure is a non-working electrode connected to a polarity opposite to that of drug ions. 42, an electrolyte solution holding portion that is electrically connected to the non-working side electrode 42 and holds the electrolyte solution, and is disposed on the front surface of the electrolyte solution holding portion, and selectively passes ions opposite to the drug ions What is necessary is just to have at least a non-action side ion selective membrane.

Sectional drawing which shows the iontophoresis apparatus which concerns on Example 1 of this invention. Sectional drawing similar to FIG. 1 which shows the iontophoresis apparatus based on Example 2 of this invention.

Explanation of symbols

DESCRIPTION OF SYMBOLS 10, 60 ... Iontophoresis apparatus 12 ... DC power supply 20, 21 ... Working side electrode structure 22 ... Working side electrode 24 ... Electrolyte holding part 26 ... Second ion selective membrane 28, 32 ... Chemical liquid holding part 33 ... First ion selective membrane (working side ion selective membrane)
34 ... Chemical solution replenishment unit 40 ... Non-working side electrode structure 42 ... Non-working side electrode 44 ... Second electrolyte solution holding unit 46 ... Third ion selective membrane 48 ... Third electrolyte solution holding unit 50 ... Non-working side ion selection Sex membrane

Claims (7)

Working and non-working electrode structures used to administer drug ions by iontophoresis and are connected to these working and non-working electrode structures with different polarities DC power supply,
The working electrode structure includes a working electrode connected to the same kind of polarity as the drug ion in the DC power source, and a drug solution that is electrically connected to the working electrode and holds the drug that becomes the drug ion. And an iontophoresis device, wherein the drug held in the drug solution holding unit is at least one of a dextran derivative and a partially degraded dextran. In claim 1,
The drug solution holding section impregnates the drug on a working ion selective membrane that selectively allows the same kind of ions as the drug ions to pass through, or is opposite to the working electrode of the working ion selective membrane. An iontophoresis device, characterized in that it is configured to be applied to any of the above. In claim 1,
The iontophoresis device, wherein the chemical solution holding unit is a mixture of the drug and a gel. In claim 2,
Between the working side electrode and the working side ion selective membrane, an electrolytic solution holding unit, a second ion selective membrane, and a chemical solution replenishing unit are provided in this order from the working side electrode, The chemical solution replenishing part holds at least one of dextran sulfate and partially decomposed dextran, and the second ion selective membrane is configured to selectively pass ions opposite to the drug ions. Iontophoresis device. Working and non-working electrode structures used to administer drug ions by iontophoresis and are connected to these working and non-working electrode structures with different polarities DC power supply,
The working electrode structure includes a working electrode connected to the same kind of polarity as the drug ion in the DC power source, and a drug solution that is electrically connected to the working electrode and holds the drug that becomes the drug ion. A holding unit and an active ion-selective membrane that is arranged on the front surface of the drug solution holding unit and selectively allows the same kind of ions as the drug ions to pass therethrough,
The non-working side electrode structure includes a non-working side electrode connected to a polarity opposite to that of the drug ion in the DC power source, and an electrolytic solution that is electrically connected to the non-working side electrode and holds the electrolytic solution A holding unit and a non-working side ion selective membrane that is disposed on the front surface of the electrolyte solution holding unit and selectively allows ions opposite to the drug ions to pass therethrough,
An iontophoresis device, wherein the drug held in the drug solution holding part is at least one of a dextran derivative and a partially decomposed dextran. In claim 5,
The working electrode structure is disposed on the front surface of the working electrode, the front surface of the working electrode, and holds an electrolytic solution, and is disposed on the front surface of the electrolytic solution holding portion, and the drug ions A second ion-selective membrane that selectively allows opposite ions to pass through; the chemical solution holding portion disposed in front of the second ion selective membrane; and the working ion disposed in front of the chemical solution holding portion. An iontophoresis device comprising: a selective membrane. In claim 5 or 6,
The non-working side electrode structure includes the non-working side electrode, a second electrolytic solution holding unit that is disposed in front of the non-working side electrode, and holds the second electrolytic solution, and the second electrolytic solution holding unit A third ion-selective membrane that is disposed on the front surface and selectively allows ions of the same kind as the drug ions to pass therethrough; a third electrolyte solution holding unit that is disposed on the front surface of the third ion-selective membrane; An iontophoresis device comprising: the non-working side ion selective membrane disposed on the front surface of the electrolyte solution holding unit.

Images